HMSY vs. TRHC: Which Stock Is the Better Value Option?

Avanos Medical (AVNS) continues to benefit from strong performing segments and robust product portfolio. However, stiff competition remains a concern.

Nevro (NVRO) received CE mark approval for the Senza Omnia SCS system, which is likely to boost its international presence.

Shares of HMS Holdings (NASDAQ:HMSY) rose 9.5% in pre-market session after the company reported Q1 results.Quarterly Results Earnings per share rose 14.29% over the past year to $0.32, which beat the estimate of $0.25.Revenue of $171,412,000 rose by 15.86% year over year, which beat the estimate of $162,320,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 08, 2020View more earnings on HMSYWebcast URL: https://edge.media-server.com/mmc/p/zyqgxxksTechnicals 52-week high: $40.67Company's 52-week low was at $18.20Price action over last quarter: Up 25.16%Company Overview HMS Holdings Corp is a United States-based holding company that conducts businesses through its operating subsidiaries. The company offers services that help customers contain healthcare insurance benefit costs. Its primary offerings comprise coordination of benefits, payment integrity, and eligibility verification. The coordination of benefits service ensures the right party pays a health claim. The payment integrity service ensures the billing and/or payment is accurate and appropriate. The eligibility verification service ensures individuals meet qualifying criteria for healthcare programs. The company's customers include Medicaid agencies, government health agencies, health plans, government and private employers, and others. The company operates only within the United States.See more from Benzinga * Recap: Spire Q2 Earnings * New Jersey Resources: Q2 Earnings Insights * Recap: Avista Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Baxter (BAX) receives the CE marking and regulatory approval for the Evo IQ Syringe Infusion system that will help in optimizing efficiency for clinicians.

Investor confidence is high in Surmodics (SRDX) stock, thanks to solid prospects.

Ladies and gentlemen, thank you for standing by, and welcome to the HMS Q1 2020 Earnings Conference Call. Joining me are Bill Lucia, our Chairman and Chief Executive Officer; and Jeff Sherman, our Chief Financial Officer. Today's press release highlighting our financial results is posted on our IR website.

Q1 2020 HMS Holdings Corp Earnings Call

HMS Holdings (HMSY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

HMS Holdings (HMSY) delivered earnings and revenue surprises of 28.00% and 5.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

HMS Holdings (HMSY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HMS Holdings Corp. (HMSY) today announced that it has changed the format of its 2020 annual meeting of shareholders to a virtual only meeting, due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being of meeting participants. As described in the proxy materials for the Annual Meeting distributed beginning on April 17, 2020, shareholders at the close of business on the record date, April 2, 2020, and holders of valid proxies are entitled to attend the Annual Meeting. To be admitted to the meeting at www.virtualshareholdermeeting.com/HMSY2020, such persons must enter the 16-digit voting control number found on their proxy card, voting instruction form, or notice of internet availability of proxy materials.

1Q'20 Total Revenue of $171.4 Million, (+15.9%) vs. 1Q'191Q'20 Net income of $12.7 Million vs. $19.6 Million in 1Q'191Q'20 EPS of  $0.14 Per Diluted Share vs. $0.22 per Diluted.

HMS Holdings (HMSY) witnessed revenue growth at COB and PI segments in Q1.

OPKO Health's (OPK) subsidiary, BioReference Laboratories collaborates with MagnaCare to offer antibody testing to Labor groups in New York metropolitan area.

After looking at HMS Holdings Corp.'s (NasdaqGS:HMSY) latest earnings announcement (31 March 2020), I found it useful...

ResMed (RMD) global sales increase on ramped-up demand for its critical care support products.

This development, which is in response to the challenges brought on by the pandemic, is expected to boost Varian's (VAR) Oncology segment.

In 2009, Bill Lucia was appointed CEO of HMS Holdings Corp. (NASDAQ:HMSY). This analysis aims first to contrast CEO...

IRVING, Texas, May 11, 2020 -- HMS Holdings Corp.  (Nasdaq: HMSY) today announced its management team is scheduled to participate in the BofA Securities Health Care Conference.